Evropská unie - španělština - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil clorhidrato de - neoplasias colorrectales - agentes antineoplásicos - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Evropská unie - španělština - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - la carmustina - hodgkin disease; lymphoma, non-hodgkin - agentes antineoplásicos - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida

Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida

Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida

Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida

Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida

Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida

Evropská unie - španělština - EMA (European Medicines Agency)

roche registration gmbh - vismodegib - carcinoma, célula basal - agentes antineoplásicos - erivedge está indicado para el tratamiento de pacientes adultos con:- sintomático metastásico de células basales y el carcinoma localmente avanzado de carcinoma de células basales inapropiado para la cirugía o la radioterapia.

Evropská unie - španělština - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - insuficiencia cardíaca - agentes que actúan sobre el sistema renina-angiotensina - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.